According to a new market report published by Lucintel, the future of the hydroxychloroquine market looks promising with opportunities in hospitals and clinics. The global hydroxychloroquine market is expected to grow with a CAGR of 34% from 2020 to 2025. The major growth drivers for this market are the recent outbreak of viruses, such as coronavirus disease (COVID-19); increasing incidence of malaria in developing countries; and rising autoimmune diseases, such as rheumatoid arthritis and lupus erythematosus.
To download report brochure, please go to https://www.lucintel.com/hydroxychloroquine-market.aspx and click "download brochure" tab from the menu
A hydroxychloroquine is a disease modifying anti-rheumatic drug (DMARD) prescribed in the treatment of malaria, rheumatoid arthritis, and other autoimmune diseases. In this market, 200 mg, 400 mg, and 800 mg are the major dosage types. Lucintel forecasts that 400 mg will remain the largest dosage type segment over the forecast period due to increasing prevalence of autoimmune diseases and malaria.
Within this market, COVID-19 will remain the highest growing application segment over the forecast period due to rapidly increasing cases of COVID-19 all over the world.
Asia Pacific will remain the largest region over the forecast period due to rising cases of maleria, rapidly increasing cases of COVID-19, and presence of major pharmaceutical manufacturing units in the region.
Novartis, Amneal Pharmaceuticals, Laurus Labs, Prasco Laboratories, Cardinal Health, Advanz Pharma, Dr. Reddy's Laboratories, Covis Pharmaceuticals, Mylan, and McKesson are among the major suppliers in the global hydroxychloroquine market.
Lucintel, a leading global strategic consulting and market research firm, has analyzed growth opportunities in the global hydroxychloroquine market by dosage type, sales channel, application, and region. Lucintel has prepared a comprehensive research report titled “Growth Opportunities in the Global Hydroxychloroquine Market 2020-2025: Trends, Forecast, and Opportunity Analysis.” This Lucintel report serves as a catalyst for growth strategy, as it provides comprehensive data and analysis on trends, key drivers, and directions. The study includes trends and forecast for the global hydroxychloroquine market by dosage type, sales channel, application, and region as follows:
By Dosage Type [Value ($ Million) shipment analysis for 2014 – 2025]:
By Sales Channel [Value ($ Million) shipment analysis for 2014 – 2025]:
By Application [Value ($ Million) shipment analysis for 2014 – 2025]:
Coronavirus Disease (COVID-19)
Malaria
Rheumatoid Arthritis
Lupus Erythematosus
Others
By Region [Value ($ Million) shipment analysis for 2014 – 2025]:
United States
Canada
Mexico
United Kingdom
Germany
France
This 150-page research report will enable you to make confident business decisions in this globally competitive marketplace. For a detailed table of contents, contact Lucintel at +1-972-636-5056 or visit us at helpdesk@lucintel.com.
About Lucintel
Lucintel, the premier global Management Consulting and market research firm, creates winning strategies for growth. It offers market assessments, competitive analysis, opportunity analysis, Growth Consulting, M&A, and Due diligence services to executives and key decision makers in a variety of industries. For further information, visit www.lucintel.com.